Related references
Note: Only part of the references are listed.Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
Patrick O. Perche et al.
ANNALS OF PHARMACOTHERAPY (2023)
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Xiaoyun Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Madison Alexander et al.
PHARMACEUTICALS (2022)
Design, synthesis and structure-activity relationship studies of pyrido [2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors
Wenhong Su et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands
Maria-Elena Liosi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies
Sean P. Henry et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Naoya Shindo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
Chunjian Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
UniProt: the universal protein knowledgebase in 2021
Alex Bateman et al.
NUCLEIC ACIDS RESEARCH (2021)
Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant
Ana S. Newton et al.
TETRAHEDRON LETTERS (2021)
Recent advances in the development of covalent inhibitors
Hyunsoo Kim et al.
RSC MEDICINAL CHEMISTRY (2021)
Metadynamics as a Postprocessing Method for Virtual Screening with Application to the Pseudokinase Domain of JAK2
Kara J. Cutrona et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core
Maria-Elena Liosi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors
Kirsten McAulay et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution
Adam Birkholz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Characterising covalent warhead reactivity
James S. Martin et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Xanthatin inhibits STAT3 and NF-κB signalling by covalently binding to JAK and IKK kinases
Man Liu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Stephen T. Wrobleski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
Liyang Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
The Cysteinome of Protein Kinases as a Target in Drug Development
Apirat Chaikuad et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors
Linhong He et al.
MOLECULAR DIVERSITY (2018)
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
Agustin Casimiro-Garcia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
Paul A. Jackson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography
Albert H. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders
David E. Puleo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules
Ana S. Newton et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Discovery of highly potent, selective, covalent inhibitors of JAK3
James Kempson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis
Linhong He et al.
ARCHIV DER PHARMAZIE (2017)
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Michael Forster et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases
Angela V. Toms et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
Mark Zak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Efficient Drug Lead Discovery and Optimization
William L. Jorgensen
ACCOUNTS OF CHEMICAL RESEARCH (2009)
Scope of the suzuki -: Miyaura aminoethylation reaction using organotrifluoroborates
Gary A. Molander et al.
JOURNAL OF ORGANIC CHEMISTRY (2007)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling
TC Yeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
M Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
